21561 ⎘
Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a NS, NS, NS, N chelating group chelates from cyclic ligands, e.g. DOTA
HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#2COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX
#3Compounds Targeting Carbonic Anhydrase IX and Uses Thereof
#4MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF
#5USE OF EXOSOME, COMPLEX COMPRISING EXOSOME, TRACER, AND PREPARATION METHOD THEREOF
#668GA- AND 64CU -NODAGA-E[C(RGDYK)]2 FOR USE AS PET TRACERS IN THE IMAGING OF ANGIOGENESIS IN HUMANS
#7KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
#8NEUROTENSIN RECEPTOR LIGANDS
#9GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF
#10PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64
#11PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64
#12MULTI-TARGETING COMPOUND AND USE THEREOF
#13FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#14HETERODIMER AND RADIOACTIVE MEDICAL USE THEREOF
#15DIMERIC RADIOPHARMACEUTICALS, COMPOSITIONS THEREOF AND USES THEREOF
#16AMPHIPHILIC COMPOUNDS FOR ATTENUATING NEUROTOXICITY OF AMYLOID-beta OLIGOMERS AND DIAGNOSTIC METHODS
#17Dual mode radiotracer and -therapeutics
#18USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#19USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#20PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF
#21IN VIVO TRANSITION METAL DETECTION
#22COPPER-64 COMPOSITIONS AND FORMULATIONS
#23RADIOPHARMACEUTICAL COMPOSITION AND METHODS
#24RADIOPHARMACEUTICALS
#25DOTA-HAPTEN COMPOSITIONS FOR ANTI-DOTA/ANTI-TUMOR ANTIGEN BISPECIFIC ANTIBODY PRETARGETED RADIOIMMUNOTHERAPY
#26ZWITTERIONIC METAL CHELATORS
#27ZWITTERIONIC METAL CHELATORS
#28Cancer-Targeted Alpha-Particle Therapeutic Vehicles For Treatment Of Cancer
#29METHODS FOR TREATING TUMORS
#30LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP
#31METHOD OF TREATING PROSTATE CANCER
#32PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS
#33Stable, concentrated radionuclide complex solutions
#34Alpha Emitter Compositions And Methods
#35LABELING PRECURSORS WITH SQUARIC ACID COUPLING
#36PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64
#37PROCESSES FOR PREPARING RADIOLABELLED CONJUGATES
#38BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP
#39PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64
#40IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
#41METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
#42Metallophore-Radionuclide Complex as Nuclear Imaging Contrast Agents
#43MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER
#44Stable, concentrated radionuclide complex solutions
#45PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
#46IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
#47PSMA TARGETED RADIOHALOGENATED UREA-POLYAMINOCARBOXYLATES FOR CANCER RADIOTHERAPY
#48Hydroxamic Acid Macrocyclic Agents With Pendant Chelating Moieties And Complexes Thereof
#49MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER
#50IMPROVED ALUMINUM FLUORIDE RADIOSYNTHESIS OF [18F]DK222
#51DUAL-TARGETING COMPOUND FOR FIBROBLAST ACTIVATION PROTEIN (FAP) AND INTEGRIN avB3, PREPARATION METHOD THEREFOR AND USE THEREOF
#52COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY
#53[177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOF
#54DUAL MODE RADIOTRACER AND-THERAPEUTICS
#55PEPTIDE UREA DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE UREA DERIVATIVE, AND APPLICATION OF PEPTIDE UREA DERIVATIVE
#56CLEAVABLE RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF
#57COMPLEXES FOR CANCER TREATMENT AND IMAGING
#58ZWITTERIONIC METAL CHELATORS
#59MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF
#60MACROCYCLIC COMPOUNDS AND METHODS OF MAKING THE SAME
#61ZWITTERIONIC METAL CHELATORS
#62Stable, concentrated radionuclide complex solutions
#63Stable, concentrated radionuclide complex solutions
#64RADIOPHARMACEUTICALS
#65NOVEL BISPIDINE-BASED METAL CHELATING LIGANDS DISPLAYING GOOD RELAXIVITY
#66PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
#67COMPOSITIONS AND METHODS OF TREATING MELANOMA
#68DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF
#69Stable, concentrated radionuclide complex solutions
#70Formulations Comprising a SADA Complex
#71PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF
#72COMPOUNDS AND RADIOLIGANDS FOR TARGETING NEUROTENSIN RECEPTOR AND USES THEREOF
#73LIGANDS AND THEIR USE
#74MACROCYCLE CONTAINING COMPOUNDS AND RADIOLABELLED COMPLEXES THEREOF, AS LIGANDS IN TARGETED RADIOTHERAPY APPLICATIONS
#75NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF
#76COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES
#77COMPOSITIONS AND METHODS OF TREATING MELANOMA
#78GRANZYME B DIRECTED IMAGING AND THERAPY
#79METHODS OF PREPARATION OF 18F LABELLED SILYL-FLUORIDE COMPOUNDS
#80USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#81Cleavable radioligands for targeting cell surface receptors and uses thereof
#82RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY
#83LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER
#84Purification process for the preparation of non-carrier added copper-64
#85NOVEL COMPOUND COMPRISING ESTER GROUP AND USES THEREOF
#86PURIFICATION PROCESS FOR THE PREPARATION OF NON-CARRIER ADDED COPPER-64
#87METHODS AND MATERIALS FOR COMBINING BIOLOGICS WITH MULTIPLE CHELATORS
#88Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)
#89Compounds and radioligands for targeting neurotensin receptor and uses thereof
#90TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF
#91Stable, concentrated radionuclide complex solutions
#92Stable, concentrated radionuclide complex solutions
#93Stable, concentrated radionuclide complex solutions
#94Stable, concentrated radionuclide complex solutions
#95TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTION
#96RIGIDIFIED MACROCYCLES, COMPLEXES WITH RADIONUCLIDES, AND USE IN TARGETED RADIOTHERAPY OF CANCER
#97BIFUNCTIONAL CHELATORS AND CONJUGATES
#98CONJUGATES COMPRISING COVALENT BINDERS FOR TARGETING INTRACELLULAR KRAS G12C PROTEINS
#99COMPOSITION CONTAINING BUFFER
#100DEVELOPMENT OF CD163 TARGETING AGENT FOR IMAGING AND THERAPY
#101COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND AND NAPOX
#102Chiral TACN/NOTA compounds/derivatives with and without metals for application
#103COMBINATION COMPRISING A NEUROTENSIN RECEPTOR BINDING COMPOUND, GEMCITABINE AND NAB-PACLITAXEL
#104METHOD OF TREATING PROSTATE CANCER
#105NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
#106HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#107COMPOUND AND RADIOACTIVE LABELING COMPOUND
#108HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#109HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#110HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#111FIBROBLAST ACTIVATION PROTEIN (FAP) TARGETED IMAGING AND THERAPY IN FIBROSIS
#112GRANZYME B DIRECTED IMAGING AND THERAPY
#113MULTIMERIC CHELATOR COMPOUNDS FOR USE IN TARGETED RADIOTHERAPY
#114BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
#115DISCRETE PEG CONSTRUCTS
#116FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF
#117METHOD OF PREPARING ESTRADIOL DERIVATIVES BY SOLID-PHASE SYNTHESIS
#118FIBRIN-BINDING COMPOUNDS FOR IMAGING AND TREATMENT
#119RADIOPHARMACEUTICAL AND METHODS
#120Bifunctional chelators and conjugates
#121Solid phase synthesis of glutamate-urea-lysine derived (GUL derived) prostate-specific membrane antigen (PSMA) targeting conjugates and their use as precursors for therapeutic and/or diagnostic agents
#122Bicyclic peptide ligands specific for MT1-MMP
#123Stable, concentrated radionuclide complex solutions
#124MACROCYCLIC LIGANDS WITH PENDANT CHELATING MOIETIES AND COMPLEXES THEREOF
#125TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES
#126RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
#127PT(IV) CHEMOTHERAPEUTIC PRODRUG AND CONTROLLED RELEASE THEREOF FOR TREATMENT OF TUMORS
#128RADIATION-ACTIVATED TETRAVALENT PLATINUM COMPLEX AND USE THEREOF
#129Purification process for the preparation of non-carrier added copper-64
#130Purification process for the preparation of non-carrier added copper-64
#131METHODS OF DIAGNOSING AND PROGNOSING CANCERS OF THE HEAD AND NECK
#132Purification process for the preparation of non-carrier added copper-64
#133THERAPEUTIC, RADIOLABELED NANOPARTICLES AND METHODS OF USE THEREOF
#134Truncated Evans Blue modified fibroblast activation protein inhibitor, preparation method and application thereof
#135BIFUNCTIONAL MACROCYCLIC CHELATE, CONJUGATE, METAL COMPLEX AND USE THEREOF
#136MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER
#137Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)
#138Theranostic Silicon-Fluoride Heteroaromatic Systems and Methods Thereof
#139Purification process for the preparation of non-carrier added copper-64
#140RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER
#141SYSTEMS FOR IN VIVO MONITORING OF IMMUNE CELLS IN PATIENTS UNDERGOING CELLULAR IMMUNOTHERAPY
#142FORMULATIONS AND KITS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING
#143FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO
#144Long-Lived Gadolinium Based Tumor Targeted Imaging and Therapy Agents
#145RADIOPHARMACEUTICAL AND METHODS
#146ANTI-CD123 AFFINITY REAGENTS AND RELATED METHODS FOR TARGETED RADIOIMMUNOTHERAPY FOR THE TREATMENT OF ACUTE LEUKEMIA AND OTHER CD123+ NEOPLASMS
#147OXINE-CONTAINING CELL RADIOLABELLING AGENTS
#148Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
#149ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
#150RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#151Method and device for direct production of radio-isotope based cancer treatment pharmaceuticals
#152NON-INTUITIVE COMBINATION OF DRUG DELIVERY CARRIERS OF THE SAME DRUG FOR SYNERGISTIC GROWTH DELAY OF SOLID TUMORS
#153ANTI-GD2 SADA CONJUGATES AND USES THEREOF
#154COMPOSITIONS AND METHODS OF TARGETING AND IMAGING AGED MICROGLIA WITH Aß PEPTIDE AMINO ACID RESIDUES FOR V-DOMAIN BINDING OF RAGE
#155MULTIFUNCTIONAL COMPOUNDS FOR USE IN MEDICAL IMAGING AND THERAPY
#156PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
#157NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF, OR METAL COMPLEX THEREOF
#158PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY
#159RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN
#160COMPOUND AND RADIOACTIVE LABELING COMPOUND
#161Macrocyclic Chelators and Methods of Use Thereof
#162FAPI dimer compound, FAPI dimer-based positron emission tomography (PET) imaging agent for tumor diagnosis, and preparation method and use thereof
#163COMPOSITION, KIT AND METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
#164MULTIMODAL FLUORINE-CY3/5/7-DOTA-HAPTEN COMPOSITIONS, DIAGNOSTICS, FLUORESCENCE GUIDED SURGERY AND RADIOIMMUNOTHERAPY
#165RI-LABELED HUMANIZED ANTIBODY
#166Purification process for the preparation of non-carrier added copper-64
#167IGF-1R MONOCLONAL ANTIBODIES AND USES THEREOF
#168Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
#169RADIOLABELLED TARGETING LIGANDS
#170PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETED HIGH-AFFINITY AGENTS FOR ENDORADIOTHERAPY OF PROSTATE CANCER
#171METAL CHELATING AGENTS AND METHODS OF USING THE SAME
#172Purification process for the preparation of non-carrier added copper-64
#173A DOTA binding chimeric antigen receptor for cellular therapy
#174LOW MOLECULAR WEIGHT AND POLYAMIDOAMINE (PAMAM) DENDRIMER BASED PSMA-SPECIFIC DUAL CONTRAST AGENTS FOR OPTICAL AND PHOTOACOUSTIC IMAGING AND THERANOSTIC AGENTS FOR TREATING PROSTATE CANCER
#175RADIOPHARMACEUTICAL AND METHODS
#176DUAL MODE RADIOTRACER AND -THERAPEUTICS
#177FAP-targeted radiopharmaceuticals and imaging agents, and uses related thereto
#178Labeling precursors with squaric acid coupling
#179Methods and kits for diagnosis of cancer and prediction of therapeutic value
#180FORMULATIONS OF PSMA IMAGING AGENTS
#181NATURAL CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES
#182RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASE DIAGNOSIS AND THERAPY
#183COMPOSITIONS AND METHODS FOR DIAGNOSING VIRAL INFECTIONS INCLUDING COVID-19 AND FOR INFECTION SEVERITY MONITORING AS WELL AS TARGETED DETECTION OF CYTOKINE STORM
#184KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
#185COMBINATION RADIOIMMUNOTHERAPY AND CD47 BLOCKADE IN THE TREATMENT OF CANCER
#186Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
#187DOTMP kit formulations for radioisotopes
#188KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
#189PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS AND USES THEREOF
#190ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS
#191METHOD FOR SYNTHESIZING ZIRCONIUM COMPLEX
#192SYNTHESIS METHODS AND COMPOSITIONS OF LOW INTERMEDIATE AND LOW DICHELATE INTERMEDIATE CONTRAST AGENTS
#193NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER
#194NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY
#195FAP-ACTIVATED RADIOTHERANOSTICS AND USES RELATED THERETO
#196Imaging and treatment of pathophysiologic conditions by Cerenkov radiation
#197INDUCING FAVORABLE EFFECTS ON TUMOR MICROENVIRONMENT VIA ADMINISTRATION OF NANOPARTICLE COMPOSITIONS
#198Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
#199HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF
#200MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER
#201CHELATORS AND METHODS OF MAKING AND USING SAME
#202Chelating platform for delivery of radionuclides
#203RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULES
#204COMPOSITIONS AND METHODS FOR RADIOTHERAPY USING CHELATED RADIOTHERAPEUTIC AGENTS AND NON-TARGET TISSUE BLOCKADE
#205METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY
#206ONE STEP 64Cu-BaBaSar-RGD2 PRODUCTION METHOD
#207Compounds for positron emission tomography
#208METHODS OF TREATING CANCER
#209CANCER DIAGNOSTIC IMAGING AGENTS
#210COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX
#211Compositions and methods of treating melanoma
#212CXCR4 gamete molecular structure and method thereof
#213Actinium-225 and checkpoint inhibitor combination therapy
#214RADIODRUG FOR DIAGNOSTIC/THERAPEUTIC USE IN NUCLEAR MEDICINE AND RADIO-GUIDED MEDICINE
#215COMPOSITIONS AND METHODS OF TREATING MELANOMA
#216Purification process for the preparation of non-carrier added copper-64
#217Radiopharmaceutical and methods
#218DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF
#219Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy
#220Methods for Synthesis of Radionuclide Complex
#221BIODEGRADABLE ADHESIVE WITH RADIOISOTOPES
#222Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
#223Alpha emitter compositions and methods
#224RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE
#225Multi-Modal Contrast Agent For Medical Imaging
#226ANTIBODIES FOR CHELATED RADIONUCLIDES AND CLEARING AGENTS
#227METAL COMPLEXES AND FLUORINATION THEREOF
#228REAGENT FOR BIOCONJUGATION VIA IRREVERSIBLE REBRIDGING OF DISULFIDE LINKAGES
#229BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE
#230Bicyclic peptide ligands specific for MT1-MMP
#231CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE
#232MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER
#233RADIOPHARMACEUTICAL AND METHODS
#234PET TRACER FOR IMAGING OF NEUROENDOCRINE TUMORS
#235Radiopharmaceutical and methods
#236COMPOSITIONS AND METHODS FOR DETECTING ACE2 EXPRESSION PROFILES
#237CONJUGATES FOR DETECTION OF AXILLARY LYMPH NODE METASTASES
#238Fibroblast activation protein (FAP) targeted imaging and therapy in fibrosis
#239COMPLEX POLYSACCHARIDE-BOUND RADIOISOTOPE CHELATES AND METHODS OF TREATING MALIGNANCIES THEREWITH
#240MACROCYCLIC CHELATES AND USES THEREOF
#241COMPOSITIONS AND METHODS FOR MEASURING OXIDATIVE STRESS
#242MARKING PRECURSOR WITH SQUARIC ACID COUPLING
#243Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
#244MINIGASTRIN DERIVATES, IN PARTICULAR FOR USE IN CCK2 RECEPTOR POSITIVE TUMOUR DIAGNOSIS AND/OR TREATMENT
#245Combination Therapy
#246Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand
#247Ri-labeled humanized antibody
#248Radiolabeled compounds targeting the prostate-specific membrane antigen
#249Imaging Agents
#250DESIGN AND DEVELOPMENT OF NEUROKININ-1 RECEPTOR-BINDING AGENT DELIVERY CONJUGATES
#251N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy
#252RADIOACTIVE IMIDAZOTHIADIAZOLE DERIVATIVE COMPOUND
#253Methods for Synthesis of Radionuclide Complex
#254COMPOSITIONS AND METHODS FOR IMAGING
#255Method for extraction and purification of 68GA
#256Multi-specific antibodies with affinity for human A33 antigen and DOTA metal complex and uses thereof
#257TETRAZINES FOR HIGH CLICK CONJUGATION YIELD IN VIVO AND HIGH CLICK RELEASE YIELD
#258RADIOIMMUNOCONJUGATES AND CHECKPOINT INHIBITOR COMBINATION THERAPY
#259RADIOIMMUNOCONJUGATES AND DNA DAMAGE AND REPAIR INHIBITOR COMBINATION THERAPY
#260Composition for radiation treatment of intracavitary or metastatic deposits of malignancy and method for treatment therewith
#261METHOD OF FORMING AND SEPARATING TIN(II) FROM TIN(IV)
#262COMPLEX POLYSACCHARIDE-BOUND RADIOISOTOPE CHELATES AND METHODS OF TREATING MALIGNANCIES THEREWITH
#263Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
#264Chiral cyclen compounds and their uses
#265TRIAZAMACROCYCLE-DERIVED CHELATOR COMPOSITIONS FOR COORDINATION OF IMAGING AND THERAPY METAL IONS AND METHODS OF USING SAME
#266MONO-, DI- OR POLYSACCHARIDE USED AS METAL INHIBITOR IN THE PREPARATION OF 68GA-CHELATE-FUNCTIONALIZED TARGETING AGENT
#267BISPECIFIC AFFINITY REAGENT AND RELATED METHODS FOR PRETARGETED RADIOIMMUNOTHERAPY AGAINST CD45+ CELL
#268KIT FOR RADIOLABELLING WITH 68GA COMPRISING A METAL INHIBITOR
#269Methods and apparatuses for treating tumors
#270ALPHA PARTICLE FORMULATIONS FOR TREATMENT OF SOLID TUMORS
#271Polymeric core-shell particles
#272Compositions for chelating metals at low temperatures
#273Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
#274Labeled inhibitors of prostate specific membrane antigen (PSMA) as agents for the treatment of prostate cancer
#275Bispecific antibodies specific for treating hematological malignancies
#276Modified antibody and radioactive metal-labelled antibody
#277Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
#278Method of use for therapeutic bone agents
#279TRIFUNCTIONAL CONSTRUCTS WITH TUNABLE PHARMACOKINETICS USEFUL IN IMAGING AND ANTI-TUMOR THERAPIES
#280Radioactive compound for treatment of melanoma and use thereof
#281NEUROTENSIN RECEPTOR LIGANDS
#282Macrocyclic complexes of alpha-emitting radionuclides and their use in targeted radiotherapy of cancer
#283DAZA chelators as ligands in liver imaging
#284TCO conjugates and methods for delivery of therapeutic agents
#285Targeting compounds and methods for their production
#286Formulations and kits for radiotherapy and diagnostic imaging
#287CHELATING MOLECULES
#288Long-lived gadolinium based tumor targeted imaging and therapy agents
#289Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
#290Macrocyclic ligands with pendant chelating moieties and complexes thereof
#291Combination cancer immunotherapy with pentaaza macrocyclic ring complex
#292SODIUM SACCHARIN HAVING CONJUGATED LIGAND, DERIVATIVES THEREOF AND PROCESS FOR THE PREPARATION THEREOF
#293Time-varying kinetic modeling of high temporal-resolution dynamic pet data for multiparametric imaging
#294Double-labeled probe for molecular imaging and use thereof
#295Stable, concentrated radionuclide complex solutions
#296Macrocyclic chelators and methods of use thereof
#297NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER
#298IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA)
#299Cryptate compounds
#300Cryptate compounds